Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients may soon check their blood at home, skipping unnecessary hospital trips

NCT ID NCT06809101

Knowledge-focused Sponsor: Pomeranian Medical University Szczecin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether cancer patients can safely monitor their own blood counts at home during chemotherapy. About 265 participants from Denmark, Poland, and Germany will test a home monitoring device for several cycles. The goal is to reduce unnecessary hospital visits, lower infection risk, and improve patient independence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that home blood monitoring is practical and beneficial, leading to fewer hospital trips and better quality of life for cancer patients.
What could go wrong
This is a small pilot study, so results may not apply to all patients. Technical issues or patient errors could affect accuracy, and the approach may not be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 265 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients are patients that suffer from cancer, require outpatient chemotherapy, and have sufficient manual skills and good eyesight to independently perform home blood monitoring, and sufficient cognitive skills to operate POCT and transfer data.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * legally competent patients * aged 18 or older * diagnosed with cancer (ICD-10: C00\* - C97\*) * enrolled at the Department of Oncology/Hematology for outpatients * participants who are willing and able to give informed consent for participation in the study * participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion Exclusion Criteria: * inability to give informed consent due to mental capacity or language barrier * patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result * known bleeding disorder * bad circulation preventing the patient from getting enough blood drops to perform the test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer cancer-related condition chemotherapy-induced toxicity neoplasm neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cancer-related problem/condition Chemotherapy Chemotherapy induced anaemia Chemotherapy-induced neutropenia Chemotherapy-induced thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinic and Polyclinic for Internal Medicine C, Hematology and Oncology, Palliative Care Unit, University Medical Center

    RECRUITING

    Greifswald, Mecklenburg-Vorpommern, 17475, Germany

  • Department of Hematology and Transplantology

    RECRUITING

    Szczecin, West Pomeranian Voivodeship, 71-252, Poland

  • Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University Medical Center

    RECRUITING

    Rostock, Mecklenburg-Vorpommern, 18106, Germany

  • Department of Oncology and Radiotherapy, University Clinical Center of Gdańsk,

    RECRUITING

    Gdansk, Pomeranian Voivodeship, 80-952, Poland

  • Department of Oncology, Zealand University Hospital

    RECRUITING

    Næstved, Region Sjælland, 4700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.